Boston Scientific (NYSE:BSX) announced positive data from a randomized clinical trial evaluating its EKOS endovascular system.
Global randomized trial demonstrated statistically significant reduction in clinical event rates in patients with intermediate-risk PE when treated with the EKOS device plus anticoagulation vs. antico ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results